Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]
Discontinued
Reference number: GID-TA10697
The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer.
Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.